AlphAIalphai — Financial news for AI agents
SEC EDGARSEP 41 min read$IQV

Berkshire James G. sold (to issuer) $710K of IQV

Berkshire James G. (See Remarks) sold (to issuer) 2,713 shares of IQVIA HOLDINGS INC. (IQV) at $261.54 ($0.71M total) on 2026-09-02.

Original reporting
SEC EDGAR · Berkshire James G.
Published Sep 4, 2026, 9:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Sep 4, 2026, 10:22 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$IQV
Bearish
medium confidence
Mentioned
$IQV
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$IQVBearishLow
01

Why it matters

The disclosed sale provides fresh data for investors assessing insider sentiment and may influence short‑term trading decisions.

02

Market read

New insider sale information for IQVIA, useful for short‑term traders and sentiment analysis.

03

What to watch

Potential tax planning or diversification motives for the insider; not necessarily a bearish signal.

Relevance 5/10Novelty 7/10Timing: filing date 2026-09-04 (after market close)

Background

Form 4 filings disclose insider transactions; they are primary sources for new corporate insider activity.

Company-level read

Ticker impact

$IQVBearishMedium confidence
Context

Officer James G. Berkshire sold 2,713 shares of IQVIA for $709,558 on 2026-09-02, filing a Form 4 on 2026-09-04.

Expected impact

Possible modest dip of 1-2% in the next trading session.

Evidence & confidence

The sale size ($710K) is material for an insider but not large enough to drive a major move; market may react cautiously.

Market effects

Sector

Minimal impact on the healthcare data services sector; insider activity is isolated.

Regional

U.S. equity markets only; no broader regional effect.

Global

Limited to investors tracking IQVIA.

Counterpoint

What could challenge this read

The sale could be a routine liquidity event unrelated to company outlook; price may remain stable.

Key entities

  • Company
    IQVIA Holdings Inc.

    U.S.-listed provider of health information technologies (ticker IQV).

  • Officer
    James G. Berkshire

    Company officer who reported the sale.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

IQV insider trading history →

Related articles

AUG 30
$IQVHighAI 9/10

Will IQVIA’s Upgraded 2026 Guidance and Bookings Strength Change IQVIA Holdings' (IQV) Narrative

IQVIA Holdings (IQV) reported Q2 earnings that beat expectations, with adjusted earnings up 12.1% and revenue up 8.7% year over year. The company raised its 2026 guidance for revenue, adjusted EBITDA, and earnings, citing strong bookings and acquisitions. Management attributes the upgrade to broad-based demand and operational efficiency, including AI-driven initiatives like IQVIA.ai. The stock is projected to reach $20.4 billion in revenue and $2.0 billion in earnings by 2029, representing a 5%

simplywall.st2 min
AUG 9
$IQVMed

How IQVIA’s Medera Cardiac Gene Therapy Alliance and Raised 2026 Outlook Will Impact IQV (IQV) Investors

IQVIA Inc. said it raised full-year 2026 revenue guidance to US$17.28–US$17.48 billion, with Q3 outlook of US$4.32–US$4.39 billion, alongside reporting Q2 results and buyback activity. IQVIA also announced a collaboration with Medera Inc. on cardiac gene therapies and human-based drug discovery, linking IQVIA trial and platform capabilities to Medera programs.

simplywall.st6 min
AUG 4
$IQVMed

5 Insightful Analyst Questions From IQVIA’s Q2 Earnings Call

IQVIA reported Q2 CY2026 results with revenue of $4.37B versus $4.30B estimates and adjusted EPS of $3.15 versus $3.03, with adjusted EBITDA of $994M. Management cited 6% organic growth and strong net new bookings. Full-year revenue guidance was lifted to $17.38B and adjusted EPS to $12.90. Analysts discussed bookings, outsourcing, AI, M&A, and margins.

financialcontent.com6 min
AUG 2
Med

An IQVIA CEO Sold $26.1 Million as Bookings Hit a Record $3.15 Billion

IQVIA Holdings CEO sold about $26.1 million of stock appreciation rights with a Feb 2027 expiration, while retaining a large share position, according to the filing and article. The company reported Q2 revenue up 8.7% to $4.37B, adjusted EPS up 12.1% to $3.15, and record clinical bookings of $3.15B, raising full-year guidance to $17.475B.

yahoo.com5 min